Shots:
- The company has reported the expansion of P-III PREVENT-19 pivotal trial to evaluate the efficacy, safety, and immunogenicity of NVX-CoV2373 vs PBO in ~3,000 adolescents aged 12-17yrs. against COVID 19 across 75 sites in the US
- Patients will receive two doses of either NVX-CoV2373 or PBO given 21 days apart and participants will be monitored for safety for up to 2 yrs. following the final dose
- In a recent UK trial, Novavax’s vaccine was 96.4% effective against the original strain, 86.3% effective against the B.1.1.7/501Y.V1 variant and 89.7% overall
Click here to read full press release/ article | Ref: PRNewswire | Image: Novavax
The post Novavax Reports the Pediatric Expansion for P-III Clinical Trial of NVX-CoV2373 Against COVID-19 first appeared on PharmaShots.